Who are spirolactone's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Aldactone, Spironolacton.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/spirolactone.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

spirolactone — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

spirolactone (spirolactone) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Cardiovascular.

phase 1 Cytochrome P450 2C19, Multidrug and toxin extrusion protein 1, Nuclear receptor subfamily 1 group I member 2 Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

spirolactone (spirolactone) — Second Xiangya Hospital of Central South University.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
spirolactone TARGET	spirolactone	Second Xiangya Hospital of Central South University	phase 1		Cytochrome P450 2C19, Multidrug and toxin extrusion protein 1, Nuclear receptor subfamily 1 group I member 2
Aldactone	spironolactone	Generic (originally Searle/Pfizer)	marketed	Aldosterone Antagonist [EPC]	Cytochrome P450 2C19, Multidrug and toxin extrusion protein 1, Nuclear receptor subfamily 1 group I member 2	1960-01-01
Spironolacton	Spironolacton	ACS Biomarker	marketed		Cytochrome P450 2C19, Multidrug and toxin extrusion protein 1, Nuclear receptor subfamily 1 group I member 2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2036-10-28 — Aldactone · 9757394 · Formulation · US
2036-10-28 — Aldactone · 11395828 · Method of Use · US
2036-10-28 — Aldactone · 10888570 · Formulation · US
2036-10-28 — Aldactone · 11389461 · Formulation · US
2036-10-28 — Aldactone · 10660907 · Formulation · US
2036-10-28 — Aldactone · 10624906 · Formulation · US
2036-10-28 — Aldactone · 10493083 · Formulation · US
2036-10-28 — Aldactone · 11491166 · Formulation · US

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). spirolactone — Competitive Intelligence Brief. https://druglandscape.com/ci/spirolactone. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing